The researchers discovered a new type of neurological dementia.

Although the symptoms of the disease are similar to Alzheimer’s, the process is developing differently.

One of the areas where scientists focus on research is Alzheimer’s and dementia. The article, which was described by a scientist as al probably the most important article published in the last five years in dementia yayım, was said to have occurred in a completely different way.

In the studies on Alzheimer’s, efforts were made to determine the main factors underlying the disease based on the general belief. These studies have unfortunately resulted in a great failure. The accumulation of toxic substances, the pathological marker of Alzheimer’s disease, was considered to be the main reason, but many different arguments have emerged recently.

In the new study, it was revealed that the Alzheimer’s patients observed with dementia suffered from dementia, but not all patients with dementia suffered from Alzheimer’s disease. Neden Recent research and clinical studies in Alzheimer’s disease have taught us two things: First, everyone who is thought to have Alzheimer’s disease doesn’t have this disease, there are other factors affecting dementia, bize said Nina Silverberg of the National Institute of Aging.

According to the recently published report, the researchers reported new brain disease as limbic-premorbid age-induced TDP-43 encephalopathy or, shortly, LATE (Encephalopathy is usually the name of neuropsychiatric disorders due to some problems). Although this disease appears to have Alzheimer-like effects, pathological signals in the brain are very different.

One of the authors of the study, Julie Schneider, said they had proposed a new name for the disease. The reason for LATE was the depletion of TDP-43 proteins in the brain. In previous researches, the memory and cognitive skills of a person are lost because of the differences in the structure of TDP-43 and their concentration in a certain point.

Robert Howard of the University of London, who was not involved in the study, said that dementia had not progressed as fast as it had been predicted. Howard said LATE was seen in 20 percent of patients.

Nelson said that LATE probably requires a different treatment than AD, and the failure of the drugs in clinical tests was attributed to this factor. The researcher is hopeful that the scientific community will agree on LATE and later research will play a role in delivering the right medicines to the right patients.

Bart De Strooper, of the United Kingdom’s Bunama Research Institute, says the new research will lead scientists to reevaluate their results.

Now there is a long struggle in front of scientists and in this process, they will use the chemicals marked with biomarkers to advance their work. New research was published in Brain magazine.